Atorvastatin alleviates atherosclerosis by improving intestinal barrier function in mice and patients by modulating inflammation
International Immunopharmacology · 2025
DOI: 10.1016/j.intimp.2025.115202 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Congguo Yin und 16 weiteren Autor:innen. Beteiligte Einrichtung: The Fourth School of Clinical Medicine, Zhejiang Chinese Medicine University, Hangzhou, China; Department of Neurology, Hangzhou First People's Hospi…. Hauptthemen laut MEDLINE: Atorvastatin, Atherosclerosis, Intestinal Mucosa, Anti-Inflammatory Agents. Die Arbeit nennt 75 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Atherosclerosis (AS) is a chronic inflammatory disease caused by high cholesterol levels in the blood, leading to plaque deposition on the inside of arteries. Gastrointestinal dysfunction is a determining factor in the progression of AS by modulating inflammatory pathways. Atorvastatin (ATO) is a classic drug used to lower lipids levels, thus preventing AS. However, the underlying mechanism of ATO extends beyond lipid metabolism; it affects various pathophysiological processes, such as intestinal function. Therefore, this study attempted to measure the effect of ATO on AS and determine how it impacts mechanisms associated with gastrointestinal-vascular interaction. METHODS: ApoE-/- mice were fed a lipid and cholesterol-rich diet containing angiotensin II ad libitum for 12 weeks. Subsequently, ATO or phosphate-buffered saline solution was orally administered for another 4 weeks. Aorta, colon, and serum samples were obtained. Permeability tests were performed on human Caco-2 colon carcinoma cells using transepithelial electrical resistance. Twenty-seven patients with AS, 22 with AS treated with ATO (AS+ATO), and 17 healthy controls were enrolled in this study. Carotid artery narrowing was evaluated using carotid artery ultrasound, and blood samples were collected for enzyme-linked immunosorbent assays. RESULTS: ATO significantly alleviated aortic AS and improved blood lipid levels in mice. Simultaneously, ATO reduced intestinal permeability, inhibited immune activation inside the intestines of the mice, and decreased circulating endotoxin levels. The protective effects of ATO on intestinal barrier function were also demonstrated in an AS cell model. Clinical samples were obtained to determine the efficacy of ATO in humans, and the results primarily verified that ATO significantly decreased lipids in human serum. Moreover, a positive correlation between circulating endotoxin, inflammatory cytokines, and ZO-1 was also found in the serum of AS patients. The findings indicate the importance of intestine-vessel connections while treating stroke, providing novel therapeutic strategies for AS. CONCLUSIONS: ATO is a classic drug used for AS prevention. The findings of this study suggest that the anti-atherosclerotic effect of ATO may be mediated, at least in part, through its protective effects on intestinal barrier function and anti-inflammatory properties.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Fourth School of Clinical Medicine, Zhejiang Chinese Medicine University, Hangzhou, China; Department of Neurology, Hangzhou First People's Hospital, Hangzhou, China.
- Department of Neurology, Hangzhou First People's Hospital, Hangzhou, China.
- The Fourth School of Clinical Medicine, Zhejiang Chinese Medicine University, Hangzhou, China.
- Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, Department of Clinical Pharmacy, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
- Department of Ultrasonography, Hangzhou, First People's Hospital, Hangzhou, China.
- Department of Emergency, Hangzhou, First People's Hospital, Hangzhou, China.
Zitieren
APA
Yin, C., Li, L., Zhang, Z., Jiang, L., Ruan, J., Shi, H., Xu, C., Sang, H., Gu, X., Chen, B., Xia, W., Zhou, Y., Liu, K., Liu, F., Ni, Z., Gao, B., & Huang, J. (2025). Atorvastatin alleviates atherosclerosis by improving intestinal barrier function in mice and patients by modulating inflammation. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.115202
Vancouver
Yin C, Li L, Zhang Z, Jiang L, Ruan J, Shi H, et al. Atorvastatin alleviates atherosclerosis by improving intestinal barrier function in mice and patients by modulating inflammation. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.115202
BibTeX
@article{Yin2025,
author = {Yin, Congguo and Li, Lingfei and Zhang, Zheng and Jiang, Lin and Ruan, Jie and Shi, Huanqing and Xu, Chenke and Sang, Hongfei and Gu, Xin and Chen, Biao and Xia, Wenqing and Zhou, Yongji and Liu, Keqin and Liu, Fei and Ni, Zhumei and Gao, Beibei and Huang, Jinyu},
title = {Atorvastatin alleviates atherosclerosis by improving intestinal barrier function in mice and patients by modulating inflammation},
journal = {International Immunopharmacology},
year = {2025},
doi = {10.1016/j.intimp.2025.115202}
}
EUVIMED